Prenetics Global Limited (PRE)
NASDAQ: PRE · Real-Time Price · USD
4.360
+0.080 (1.87%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health.

The company’s consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test.

It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests.

Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk.

Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities.

The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.

Prenetics Global Limited
Prenetics Global logo
Country Hong Kong
Founded 2014
Industry Diagnostics & Research
Sector Healthcare
Employees 324
CEO Sheng Wu Yeung

Contact Details

Address:
Unit 703-706, K11 Atelier King’s Road, 728 King’s Road
Quarry Bay
Hong Kong
Phone 852 2210 9588
Website prenetics.com

Stock Details

Ticker Symbol PRE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001876431
CUSIP Number G72245106
ISIN Number KYG722451229
SIC Code 3826

Key Executives

Name Position
Walt Ling Chief Executive Officer of ACT Genomics
Joel Neoh Chief Consumer Officer and Chief Executive Officer for CircleDNA
Samantha Kwok Chief of Staff to Group Chief Executive Officer and Vice President of People & Operations
Sheng Wu Yeung Co-Founder, Chairperson and Chief Executive Officer
Dr. Chi Hung Tzang Ph.D. Co-Founder and Chief Scientific Officer
Hoi Chun Lo Chief Financial Officer
Dr. Yung Ho Wong DPHIL Chief Technology Officer
Dr. Senthil Sundaram M.D. Chief Clinical Officer

Latest SEC Filings

Date Type Title
Oct 15, 2024 6-K Report of foreign issuer
Oct 7, 2024 6-K Report of foreign issuer
Sep 27, 2024 6-K Report of foreign issuer
Sep 16, 2024 6-K Report of foreign issuer
Aug 19, 2024 6-K Report of foreign issuer
Jul 11, 2024 6-K/A Filing
Jul 11, 2024 6-K Report of foreign issuer
Jun 18, 2024 6-K Report of foreign issuer
May 21, 2024 6-K Report of foreign issuer
May 1, 2024 S-8 Securities to be offered to employees in employee benefit plans